The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2020

3 - 8 Dec 2020

Online, Virtual, United States of America

ASH 2020: CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma

ASH 2020: CAR T cell therapy effective as first-line treatment for high-risk large B-cell lymphoma

ASH 2020: Chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblastic leukaemia

ASH 2020: Chemotherapy and blinatumomab improves survival for patients with B-cell acute lymphoblast...

ASH 2020: CRISPR-edited CAR T cells enhance fight against blood cancers

ASH 2020: CRISPR-edited CAR T cells enhance fight against blood cancers

ASH 2020: Early phase studies show promise in acute myeloid leukaemia

ASH 2020: Early phase studies show promise in acute myeloid leukaemia

ASH 2020: Follow up data on venetoclax in combination with rituximab or obinutuzumab for CLL shows continued survival benefit

ASH 2020: Follow up data on venetoclax in combination with rituximab or obinutuzumab for CLL shows c...

ASH 2020: Off-the-shelf immune drug shows promise in aggressive multiple myeloma

ASH 2020: Off-the-shelf immune drug shows promise in aggressive multiple myeloma

ASH 2020: Study suggests opportunity to personalise immunotherapy for patients with large B cell lymphoma

ASH 2020: Study suggests opportunity to personalise immunotherapy for patients with large B cell lym...

ASH 2020: Researchers test CRISPR in blood disorders and extend CAR-T therapy to benefit more patients

ASH 2020: Researchers test CRISPR in blood disorders and extend CAR-T therapy to benefit more patien...

ASH 2020: Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers

ASH 2020: Venetoclax added to standard treatments shows promise in high-risk myeloid blood cancers

ASH 2020: CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma

ASH 2020: CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma

ASH 2020: Donor stem cell transplant shown to improve survival in older patients with MDS

ASH 2020: Donor stem cell transplant shown to improve survival in older patients with MDS

More from ecancer